{"filings":[{"id":1555036,"accession_number":"0001437749-26-023211","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-07-09T20:49:10+00:00","items":["4.01","9.01"],"status":"ready","headline":"BIO-key International dismisses Bush & Associates, engages M&K CPAS as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved engagement of M&K CPAS, PLLC on July 2, 2026; Bush & Associates dismissed on July 7, 2026.","Prior auditor's reports for FY2024 and FY2025 included going concern explanatory paragraph but no adverse opinion or disagreements.","No reportable events or disagreements between company and Bush & Associates during the two most recent fiscal years and subsequent interim period.","Company provided Bush & Associates with disclosures; Bush & Associates' response letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1481600,"accession_number":"0001437749-26-022880","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-07-07T12:45:22+00:00","items":["7.01","9.01"],"status":"ready","headline":"BIO-key regains Nasdaq compliance; trading resumes July 8 after hearing panel decision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearings Panel determined BIO-key regained compliance with minimum bid price and SEC filing requirements.","Trading of BKYI common stock resumes on Nasdaq Capital Market on July 8, 2026.","Company subject to Discretionary Panel Monitor for one year until July 6, 2027.","CEO cites growing recurring revenue, solid financial position, and expects significantly improved results in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":975397,"accession_number":"0001437749-26-020203","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-06-10T21:28:24+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BIO-key receives Nasdaq notice for delayed 10-Q filing; delisting hearing set for June 16","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) for failure to timely file Q1 2026 Form 10-Q.","This is an additional basis for delisting; previously appealed Nasdaq's May 6 determination to suspend trading.","Hearing before Nasdaq Hearing Panel scheduled for June 16, 2026.","No assurance that the Panel will grant continued listing or that compliance can be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482801,"accession_number":"0001437749-26-017518","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-05-18T12:30:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q1 revenue up 34% to $2.15M, net loss narrows to $(165K); sees Q2 profitability on 65% revenue jump","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $2.15M (+34% YoY); net loss improved to $(165K) from $(737K) in Q1 2025.","Gross margin 82%; cash $2.24M at quarter end; EPS $(0.15) post-reverse split.","Q2 2026 revenue guided ~$2.8M (+65% YoY); expects H1 2026 profitability vs H1 2025 net loss of $(1.9M).","Secured $1.04M license renewal with foreign bank; defense sales surpassed $2M in trailing twelve months.","Shares suspended from Nasdaq, now trading OTC under BKYI; company working to return to Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":41841,"accession_number":"0001437749-26-016455","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-05-12T20:46:03+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq suspends BKYI trading after close May 12 for failing to maintain $1 bid price for 10 consecutive days by May 4 and late Form 10-K.","Company will request a hearing before a Nasdaq Hearings Panel to appeal delisting; no guarantee of reinstatement.","Stock to be quoted on OTC Markets under symbol BKYI starting May 13; reverse stock split was effective April 30 but timing fell short.","CEO states 1H'26 revenue expected to rise 50% to $5M vs $3.3M in 1H'25; targets profitability vs $1.9M net loss in 1H'25.","Cash position expected to remain in line with year-end 2025 level; company retains listing consultants to expedite Nasdaq return."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90632,"accession_number":"0001437749-26-013905","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"BIO-key announces 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-10, effective 5:00 p.m. ET on April 29, 2026; trading begins split-adjusted April 30, 2026.","Outstanding shares reduced from ~10,852,118 to ~1,085,212; no fractional shares, rounding up to nearest whole share.","Stockholders approved the split at an April 20, 2026 special meeting; Board chose the ratio to meet Nasdaq minimum bid price requirement.","CEO Michael DePasquale stated the split intends to position the stock for bid price compliance while pursuing growth and profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90631,"accession_number":"0001437749-26-013319","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BIO-key shareholders approve reverse stock split up to 1-for-10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal approved with 4,209,160 votes for, 1,361,166 against, and 30,366 abstentions.","Board authorized to set exact ratio (1-for-2 to 1-for-10) and timing, no later than May 6, 2026.","Quorum achieved with 51.62% of outstanding shares (5,600,692 of 10,849,618) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90630,"accession_number":"0001437749-26-013049","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BIO-key receives Nasdaq non-compliance notice for delayed 10-K filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received April 16, 2026 for failure to timely file 2025 Form 10-K.","Rule violated: Nasdaq Listing Rule 5250(c)(1) for periodic financial reports.","No immediate impact on listing or trading of BKYI common stock on Nasdaq.","Company working with auditors; expects to file the 10-K next week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90629,"accession_number":"0001437749-26-012772","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key expects 50% revenue growth to ~$5M and profitability in 1H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["1H'26 revenue expected ~$5M (+50% YoY vs $3.3M); positive net income vs $1.9M loss in 1H'25.","Q1'26 rev. expected $2.2M (+37% YoY); Q2'26 rev. expected $2.8M (+65% YoY).","$1.04M expanded software license renewal with foreign retail bank; $1M+ in scanner and POS contracts.","Cash position at end of 1H'26 expected to remain in line with $2.7M at year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100317,"accession_number":"0001437749-26-010506","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key reports FY2025 revenue $6.1M, net loss $4.6M; Q1'26 revenue up 37% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $6.1M, down 12% YoY; net loss $4.6M ($0.69/sh) vs $4.3M ($2.09/sh) in 2024.","Preliminary Q1'26 revenue $2.2M, up 37% YoY and 80% vs Q4'25; expects break-even in 2026.","Cash $2.7M at year-end, up from $0.4M; book value $7.6M vs $3.8M.","Defense sector revenue over trailing 12 months exceeded $2.2M; new partnerships in India, Vietnam, Middle East, Nordics.","Operating expenses reduced 7% to $669K; SG&A down 11%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100316,"accession_number":"0001437749-26-006816","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key secures $1.04M license renewal from foreign retail bank; cash at $2.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$1.04M one-year renewal from foreign retail bank (client since 2015), up 30% YoY.","Bank's biometric deployment grew from 7M to over 30M enrolled clients.","Year-end cash position of $2.7M; management expects sufficient liquidity for growth.","Renewal includes 5% expected enrollment growth; 10,000 employees use fingerprint tech.","CEO cites growing traction in large-scale deployments to bolster working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116649,"accession_number":"0001437749-25-034997","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q3 revenue falls 28% to $1.55M; net loss widens; raises $3.1M via warrant exercise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $1.55M (down 28% YoY); net loss ($964,849) or ($0.15) per share vs ($738,959) ($0.39) in Q3'24.","Full year 2025 revenue guidance $6.5-$7M.","On Oct 27, raised $3.1M gross via warrant exercise at $1.02/share (3.09M shares); used proceeds to prepay notes.","Launched EcoID III scanner; secured Middle East defense biometric deployment.","Balance sheet: $2.0M cash at Sep 30 vs $0.4M at Dec 31; total notes outstanding $675k."],"consensus_eps_estimate":-1.224,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4853772.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116648,"accession_number":"0001437749-25-033877","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BIO-key receives Nasdaq extension to May 2026 to regain $1 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted BIO-key an additional 180-day period, until May 4, 2026, to meet the $1.00 minimum bid price rule.","The extension follows a prior notice from May 9, 2025, and is contingent on meeting all other listing requirements.","The company intends to effect a reverse stock split if necessary to cure the bid price deficiency.","Failure to comply by May 4, 2026, will result in Nasdaq delisting; company may appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116647,"accession_number":"0001437749-25-032448","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BIO-key raises $3.1M via warrant exercise, exchanges debt for equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $3.1M from exercise of 3,091,668 warrants at reduced exercise price of $1.02; new warrants for 6.18M shares at $1.02.","Net proceeds for working capital and debt repayment; $0.25 per warrant paid for new warrants.","Streeterville Capital exchanged $327,991 secured note principal for 429,027 shares; original note paid in full.","New warrants expire in 5 years; resale registration to be filed within 90 days.","Transactions in unregistered offering; Maxim Group earned 6% fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116646,"accession_number":"0001437749-25-030493","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BIO-key closes $1.13M secured note with Streeterville Capital, net $1M for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.13M senior secured promissory note; net proceeds $1M after $125K OID and $5K transaction costs.","Interest 9% per annum; maturity 18 months from September 30, 2025.","Lender may redeem up to $135K monthly starting 6 months after issuance; exit fee 7% on any principal repaid.","Note secured by substantially all company assets; mandatory prepayment of 40% of proceeds from future financings.","Covenants include timely SEC filings and maintaining Nasdaq listing; events of default allow 22% interest and acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133091,"accession_number":"0001437749-25-027454","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BIO-key shareholders approve 700k share increases to 2023 stock plan and ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2023 Stock Incentive Plan share reserve raised by 700,000 to 1,033,334 shares.","2021 Employee Stock Purchase Plan share reserve raised by 700,000 to 743,834 shares.","Shareholder approval obtained at annual meeting on August 8, 2025; amendments effective same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133090,"accession_number":"0001437749-25-026550","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BIO-key stockholders elect all director nominees and approve all proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Michael DePasquale, Kelvin Wong, Robert Michel, Emmanuel Alia, Cameron Williams with ~1M votes each; broker non-votes of ~2.7M.","Ratified Bush & Associates CPA as auditor for FY2025; 3.5M for, 461k against, 52k abstain.","Approved non-binding advisory say-on-pay: 975k for, 318k against, 7k abstain, 2.7M broker non-votes.","Amended 2023 Stock Incentive Plan and 2021 Employee Stock Purchase Plan both approved (985k and 1.02M for respectively)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133089,"accession_number":"0001437749-25-026360","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q2 revenue up 49% to $1.7M; launches CyberDefense Initiative for defense contracts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.70M vs $1.14M YoY; net loss improved to ($1.17M) or ($0.20)/share from ($1.67M) or ($1.00)/share.","Gross margin 73% vs 77% YoY due to higher hardware mix; hardware sales surged to $569K from $83K.","BIO-key launches CyberDefense Initiative targeting military/defense IAM; cites $350B EU defense spending.","Notes payable reduced by $0.4M in Q2, balance $0.3M; cash $2.3M at June 30, 2025.","Platform modernization for PortalGuard IDaaS targeted for Q4'25 release."],"consensus_eps_estimate":-1.53,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3304066.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149689,"accession_number":"0001437749-25-017237","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"BIO-key Q1 rev $1.6M, net loss widens; Nasdaq bid price deficiency notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2025 revenue $1.6M (-25% YoY); net loss $736k vs $510k; EPS ($0.16) vs ($0.32).","Cash and equivalents $3.1M at Mar 31, up from $438k at Dec 31, on warrant exercises.","Nasdaq notice on May 9: bid price below $1.00 for 30 days; compliance deadline Nov 5, 2025.","Gross margin 82.6%; SG&A down 23% YoY to $1.37M; operating expenses reduced 18%.","New partnerships: Arrow ECS Iberia, California Ed Tech JPA; deployed PortalGuard for National Bank of Egypt (30k users)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149688,"accession_number":"0001437749-25-012986","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BIO-key regains Nasdaq compliance after late 10-K filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq non-compliance notice on April 17, 2025, for failure to timely file Form 10-K.","Filed the missing 10-K on April 23, 2025.","Nasdaq confirmed compliance on April 24, 2025, closing the matter.","No immediate effect on stock listing or trading during the period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168723,"accession_number":"0001437749-25-009483","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key narrows FY2024 net loss 49% to $4.3M on revenue of $6.9M (down 11%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $4.3M ($2.10/sh) from $8.7M ($15.21/sh) in 2023, reflecting higher gross margin and lower costs.","Revenue decreased 11% to $6.9M due to exit from low-margin Swivel Secure distribution; license fee revenue up 20% to $5.2M.","Gross profit rose to $5.6M from $1.4M, benefiting from higher-margin license sales and a $3.6M hardware reserve in 2023.","Operating expenses reduced 6% to $9.7M; cash used in operations down 23% to $2.91M.","Recent partnerships include CA Ed Tech JPA (195 institutions), National Bank of Egypt, and a $910K biometric order from financial services firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168722,"accession_number":"0001437749-25-001242","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BIO-key raises ~$3.8M via warrant exercise; exchanges $834K debt for equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercised 2,061,112 existing warrants at $1.85/share, gross proceeds ~$3.8M before fees.","Issued new Series A & B warrants for up to 1,545,834 shares each at $2.15, expiring in 5 years.","Exchanged $834K of promissory note for 489,635 shares; note balance reduced to ~$738,400.","Net proceeds to be used for working capital and partial repayment of secured note.","Maxim Group acted as placement agent with 6.0% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185847,"accession_number":"0001437749-24-036582","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BIO-key swaps 19% equity stake for $5M Boumarang shares to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 595,000 shares (19% of outstanding) for 5M Boumarang shares valued at $5M ($1/share).","Transaction increased stockholders' equity by $5M, above Nasdaq's $2.5M minimum requirement.","Nasdaq approved compliance plan in Aug. 2024; this deal aims to satisfy the equity requirement.","Boumarang shares valued at $1 each based on due diligence; no public market disclosed.","Nasdaq will continue monitoring; delisting risk remains if equity drops below minimum at next report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185846,"accession_number":"0001437749-24-036492","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BIO-key acquires 5M Boumarang shares from Fiber Food in exchange for 595K shares, adding $5M assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BIO-key exchanged 595,000 shares of its common stock (19% of outstanding) for 5 million Boumarang shares valued at $5 million.","BIO-key gains put option to force Fiber Food to repurchase Boumarang shares at $5M if value drops within 9 months.","Fiber Food agrees to integrate BIO-key's IAM solutions into its offerings and introduce potential customers.","Transaction strengthens BIO-key's balance sheet with $5 million increase in stockholders' equity.","Agreement includes two-year standstill and lockup on Fiber Food's ability to transfer BIO-key shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185845,"accession_number":"0001437749-24-035433","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q3 revenue up 18% to $2.1M; net loss narrows to $0.7M from $1.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.1M vs $1.8M; license revenue rose 52% to $1.4M on expanded customer deployments.","Gross margin improved to 78.3% from 18.7%; net loss per share $0.39 vs $3.22 YoY.","Cash position strengthened to $1.8M at Sep 30 from $0.5M at Dec 31, aided by $1.9M warrant inducement.","Recent orders: $910k from financial services customer, $500k from defense ministry; 10,000 users added by British Columbia.","Full-year 2024 revenue expected to meet or exceed $7.75M achieved in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5467293.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202420,"accession_number":"0001437749-24-029307","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BIO-key raises ~$1.9M via warrant exercise; issues new warrants to investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor immediately exercised 1,030,556 existing warrants at reduced price of $1.85/share.","Gross proceeds approximately $1.9M before fees; net to fund working capital and repay secured debt.","In consideration, investor received new Series A & B warrants for another 1,030,556 shares each at $1.85.","New warrants are exercisable immediately and expire in 5 years; resale registration to be filed within 45 days.","Maxim Group acted as exclusive placement agent, receiving 6% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202419,"accession_number":"0001437749-24-027948","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BIO-key annual meeting results: all director nominees elected, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five director nominees elected with at least 349,187 votes for each; broker non-votes 667,346.","Ratification of Bush & Associates CPA as auditor for 2024 approved: 831,104 for, 112,537 against.","Non-binding advisory say-on-pay approved: 302,123 for, 101,061 against, 64,330 abstentions.","Advisory vote on frequency of say-on-pay favored 1-year (309,685 votes); company will hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202418,"accession_number":"0001437749-24-026930","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q2 2024 revenue down 42% YoY to $1.1M; net loss narrows to $1.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.1M vs $1.9M YoY; delayed ~$450k software license fees and lower project services.","Net loss improved to $1.7M ($1.00/share) from $2.6M ($4.71/share) in Q2 2023, helped by $1M prior-year hardware reserve.","Gross margin surged to 77.0% from 16.7% on absence of hardware reserve and higher services margins.","Cash used in operations in H1 2024 fell 48% to $1.1M vs $2.1M in H1 2023.","Recent wins: Williamsburg VA, LA LGBT Center, University of Iowa Hospital; launched Passkey:YOU product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3322489.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218550,"accession_number":"0001437749-24-021599","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BIO-key issues $2.36M secured note to Streeterville Capital; net proceeds $2M for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2,360,000 principal senior secured note issued to Streeterville Capital; net proceeds $2,000,000 after OID and fees.","Interest at 9% per annum, 18-month term; exit fee of 7%; monthly redemptions of up to $270k starting month 6.","Secured by substantially all assets; subsidiary Pistol Star provides guarantee.","Mandatory prepayment of 40% from future fundraising (incl. warrant exercises).","Proceeds used for general working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218549,"accession_number":"0001437749-24-020489","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q1 revenue $2.2M, net loss narrows to $0.5M; generates positive operating cash flow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M flat YoY, up 19.5% QoQ; gross margin improved to 86.3% from 40% on higher license mix and prior hardware reserve.","Net loss $0.5M ($0.32/sh) vs $1.7M ($3.51/sh) in Q1'23; operating cash flow positive $0.3M vs $1.9M used.","Operating expenses cut 9% to $2.4M; cash and equivalents $690K; accounts receivable $710K.","Expanded biometric deployment with long-term financial client drove license fee revenue up 23.6% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218548,"accession_number":"0001437749-24-020367","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BIO-key receives Nasdaq delisting notice for stockholders' equity below $2.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BIO-key on June 10, 2024 that stockholders' equity as of Dec 31, 2023 failed to meet the $2.5M minimum requirement.","Company has 45 calendar days, until July 25, 2024, to submit a plan to regain compliance.","If Nasdaq accepts the plan, it may grant an extension of up to 180 calendar days from the notice date.","If plan is not accepted or compliance not regained, BIO-key may request a hearing; delisting action stayed during hearing.","No assurance that the company will be able to regain compliance with the continued listing rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218547,"accession_number":"0001437749-24-018348","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BIO-key receives Nasdaq delisting notice for late 10-Q; restating prior periods","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 22, 2024 for non-compliance with Listing Rule 5250(c)(1) due to late 10-Q filing for quarter ended March 31, 2024.","Company remains delinquent on 2023 10-K; restating 2023 quarterly financial statements (Q1, Q2, Q3 2023).","Must submit compliance plan by June 17, 2024; potential extension to October 14, 2024 if plan accepted.","No immediate effect on listing or trading of common stock on Nasdaq Capital Market.","Company intends to file Form 10-Q and Form 10-K as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218546,"accession_number":"0001437749-24-013771","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BIO-key replaces auditor Marcum with Bush & Associates after material weakness and restatement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Marcum LLP as independent auditor on April 23, 2024; engaged Bush & Associates CPA on April 24, 2024.","Marcum's 2022 audit report included a going concern qualification; material weakness in internal control over income tax provision reported.","Company restated Q1-Q3 2023 financials per April 22, 2024 8-K; those periods should no longer be relied upon.","No disagreements with Marcum on accounting principles, but reportable events existed (material weakness and restatement).","Bush & Associates has not yet been consulted on any accounting, auditing, or financial reporting issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218545,"accession_number":"0001437749-24-012736","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["3.01","4.02","7.01","9.01"],"status":"ready","headline":"BIO-key restates FY2023 quarterly financials due to revenue recognition errors; receives Nasdaq non-compliance notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee found errors in revenue recognition at Swivel Secure Europe for Q1-Q3 2023.","Previously issued financials for Q1, Q2, Q3 2023 and related press releases no longer reliable.","Revenue overstated, accounts receivable overstated; allowances and reserves understated; net loss understated.","Nasdaq notice for late 10-K filing; 60 days to submit plan, extension possible to Oct 14, 2024.","Company plans to file restated financials and annual report as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218544,"accession_number":"0001437749-24-010505","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key reports preliminary 2023 revenue up 29% to $9.1M, net loss $(6.2M) after $2.8M inventory reserve","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2023 revenue $9.1M (+29% YoY); net loss $(6.2M) vs $(12.2M) in 2022; EPS $(11.45).","Q4'23 net loss $(4.1M) or $(5.54) per share, improved from $(6.7M) a year ago.","Took $2.8M non-cash reserve on slow-moving hardware inventory for Africa projects.","SG&A trimmed 22% to $7.3M; R&D down 26% to $2.4M.","Received $1.5M cash in Q1'24 for 2-year biometric license extension with existing customer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2181203.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238440,"accession_number":"0001437749-24-001159","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BIO-key regains Nasdaq bid-price compliance after stock closes above $1.00 for 10 sessions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["As of Jan 5, 2024, common stock closing bid price exceeded $1.00 for 10 consecutive business days.","Prior deficiency notices were reported on Jan 12, 2023 and Jul 12, 2023.","Nasdaq confirmed compliance on Jan 8, 2024, closing the matter.","Company now meets Nasdaq Listing Rule 5550(a)(2) bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255940,"accession_number":"0001437749-23-035114","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BIO-key repays $2.2M senior secured note, completes $550K private placement, eliminates long-term debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repaid $2.2M senior secured note held by AJB Capital Investments, eliminating all long-term debt.","Completed $550K private placement with Dillon Hill Investment: 872,502 shares, 2,270,335 pre-funded warrants, 4,714,285 common warrants at $0.175/unit.","Combined equity funding of $4.3M over past two months to strengthen cash and liquidity.","Revenue grew 39% to $8.6M over last four quarters; Q3'23 net loss reduced to $638K from $2.4M in Q3'22.","1-for-18 reverse stock split effective Dec 21, leaving ~1M shares outstanding and ~1.9M common stock equivalents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255939,"accession_number":"0001437749-23-034827","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","8.01","9.01"],"status":"ready","headline":"BIO-key approves 1-for-18 reverse stock split effective Dec 21 to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at ratio 1-for-6 to 1-for-20; Board set final ratio at 1-for-18.","Reverse split effective 5:00 p.m. ET Dec 20; shares trade split-adjusted Dec 21 under new CUSIP 09060C507.","Outstanding shares reduced from ~16.9M to ~941,000; no fractional shares issued, rounded up to nearest whole.","Stockholders also approved 2023 Stock Incentive Plan authorizing up to 6M shares of common stock.","CEO states reverse split positions stock for ongoing Nasdaq compliance as company executes growth goals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255938,"accession_number":"0001437749-23-031661","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BIO-key director Thomas E. Bush III resigns from board effective Nov 8, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas E. Bush III resigned from BIO-key's Board of Directors effective November 8, 2023.","Resignation was not due to any disagreement with the company's operations, policies, or practices.","No successor or replacement has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255937,"accession_number":"0001437749-23-029920","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BIO-key closes $3.75M public offering; net $3.3M to repay debt and for working capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $3.75M from sale of 21.43M units at $0.175/unit; each unit comprises one share (or pre-funded warrant) and one 5-year warrant exercisable at $0.175.","Net proceeds approximately $3.3M after deducting placement agent fees and offering expenses.","Company intends net proceeds to repay up to $2.2M of outstanding debt and for general corporate and working capital.","Offering closed October 31, 2023; Maxim Group LLC acted as sole placement agent with a 7% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255936,"accession_number":"0001437749-23-028904","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q3 revenue up 33% to $1.8M, net loss per share narrows to ($0.08) from ($0.29)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.8M (+33% YoY); gross profit $1.4M (+43%); gross margin 77% vs 71%.","Operating loss improved to ~$750K from $2.4M; net loss per share ($0.08) vs ($0.29) in Q3'22.","Nine-month revenue $6.8M (+30%); net loss reduced to $2.5M from $5.1M in year-ago period.","ARR ~$7M; secured additional order from international defense ministry customer for expanded rollout.","Cash and equivalents $0.3M; seeking expense reductions including HQ relocation to reach breakeven."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":6829804.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273343,"accession_number":"0001437749-23-023794","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q2 revenue flat at $1.9M; net loss narrows to $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.9M flat YoY; first-half revenue up 29% to $5.9M.","Q2 gross margin improved to 69% from 63%; gross profit $1.3M up 8%.","Q2 net loss narrowed to $1.4M from $1.7M; operating expenses down 10%.","Signed $0.3M defense ministry order in early Q3; expanding EMEA partnerships.","Management confident in FY2023 top-line growth and bottom-line improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5012696.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273342,"accession_number":"0001437749-23-020725","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BIO-key stockholders elect six directors, ratify auditor, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; Michael DePasquale received 2,257,370 For, 511,573 Withheld.","Ratification of Marcum LLP as auditor for FY 2023 approved with 4,139,367 For, 1,294,602 Against.","Non-binding advisory vote on executive compensation passed with 2,117,139 For, 588,218 Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273341,"accession_number":"0001437749-23-019971","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BIO-key receives additional 180-day Nasdaq compliance period until Jan 8, 2024 for bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency letter on Jan 12, 2023 for bid price below $1.00 for 30 consecutive days.","On July 12, 2023, Nasdaq granted additional 180-day period until Jan 8, 2024 to regain compliance.","To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.","Company may effect reverse stock split to cure deficiency if needed.","If not compliant by Jan 8, 2024, Nasdaq will delist and company can appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290289,"accession_number":"0001437749-23-018629","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BIO-key amends securities purchase agreement, waives defaults with AJB Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amends Dec 2022 agreement: repurchase of up to 272k commitment shares if principal paid by July 22, 2023; up to 214k if paid by Aug 21, 2023, each for $1.00.","Waives events of default related to late filing of Q1 2023 Form 10-Q and failure to timely register shares; registration waiver expires July 30, 2023.","Original $2.2M note and 700k commitment shares issued in December 2022; amendment adjusts repurchase rights based on principal payment timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290288,"accession_number":"0001437749-23-017306","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BIO-key cures Nasdaq listing deficiencies; all periodic reports now timely filed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BIO-key on June 13, 2023 that it is in compliance with Listing Rule 5250(c)(1).","Company had received deficiency notices for failure to timely file Form 10-K (year ended Dec 31, 2022) and Form 10-Q (quarter ended Mar 31, 2023).","Form 10-K was filed on June 1, 2023; Form 10-Q was filed on June 9, 2023, curing both deficiencies.","Previously closed Form 10-K matter and newly closed Form 10-Q matter remove all pending delisting risks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290287,"accession_number":"0001437749-23-016491","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BIO-key appoints Cameron E. Williams to Board of Directors and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cameron E. Williams appointed to the Board effective June 2, 2023; also joins the Audit Committee.","Williams brings over 40 years of financial and executive management experience; founded CEW Advisory Services in 2014.","Previous roles include COO of Asta Funding (2007-2009) and President of Popular Financial Holdings (1998-2007).","No arrangements or transactions with the company requiring SEC disclosure were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290286,"accession_number":"0001437749-23-016136","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BIO-key receives Nasdaq non-compliance notice for late filings; plan due June 20","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BIO-key on May 23, 2023 of non-compliance for failing to timely file Form 10-Q for Q1 2023.","Company was already delinquent on Form 10-K for year ended Dec 31, 2022.","Must submit compliance plan by June 20, 2023; if accepted, extension to Oct 16, 2023.","No immediate impact on listing or trading of common stock on Nasdaq Capital Market.","Form 12b-25 filed May 16, 2023 citing unreasonable effort to complete financial review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290285,"accession_number":"0001437749-23-014725","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BIO-key Q1 revenue rises 59% to $3.1M; net loss narrows to $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.1M (+59% YoY); gross profit $2.3M (73% margin); net loss $0.5M vs $1.0M in Q1'22.","Operating expenses flat at $2.57M; cash $0.7M; accounts receivable $3.5M; current debt $1.9M.","Capitec Bank biometric system expanded to 21.7M users; Swivel Secure project for 1.5M citizens in Central America.","Over 600 customers; growing recurring revenue; expense reduction initiatives ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3083767.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290284,"accession_number":"0001437749-23-010926","cik":1019034,"company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BIO-key receives Nasdaq non-compliance notice for late 10-K filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BIO-key on April 18, 2023, of non-compliance with Listing Rule 5250(c)(1) due to failure to file annual 10-K for FY2022.","Company has 60 days to submit a compliance plan; Nasdaq may grant up to 180 days extension until October 16, 2023.","Late filing attributed to compilation and review delays deemed undue hardship; no immediate effect on stock listing.","BIO-key intends to file the 10-K as soon as practicable to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4823333.645934066,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-24T23:59:59+00:00|290284"}